Struggling Argos Therapeutics Inc. has agreed to give its three top executives retention pay during the next month as a way of keeping them on board the company, according to a
Read More
Argos Therapeutics, Inc. reported it will terminate its study on treatment of newly diagnosed metastatic renal cell carcinoma, causing is stock to fall 68 percent on Thursday.
Read MoreArgos Therapeutics, an immune-oncology company, has enough cash to to fund its operations through the end of 2018, according to a securities filing.
Read MoreHeat Biologics and Argos Therapeutics are executing reverse stock splits in an attempt to drive up value for their respective shares.
Read More
A Hong Kong company haspurchased 7.5 million shares of stock for $1.5 million from Argos Therapeutics Inc., a biotechnology company headquartered in Durham.
Read More
Argos Therapeutics Inc., a biotechnology company headquartered in Durham, now has enough cash to last through June 2018, according to a filing Tuesday with the SEC.
Read More
